—] Shares AQUINOX PHARMACEUTICALS, INC. UNDERWRITING AGREEMENTUnderwriting Agreement • February 28th, 2014 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • New York
INDEMNIFICATION AGREEMENTIndemnification Agreement • January 28th, 2014 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • Delaware
THIS INDEMNIFICATION AGREEMENT (the “Agreement”) is made and entered into as of between AQUINOX PHARMACEUTICALS (USA) INC., a Delaware corporation (the “Company”), and (“Indemnitee”).
AQUINOX PHARMACEUTICALS, INC. AND _____________, AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF __________Warrant Agreement • March 12th, 2018 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • New York
THIS PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of [•], between AQUINOX PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
AQUINOX PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF COMMON STOCK WARRANT AGREEMENT DATED AS OF [ ], 20Common Stock Warrant Agreement • December 21st, 2015 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • New York
COMMON STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between AQUINOX PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
AQUINOX PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OF [ ], 20Warrant Agreement • December 21st, 2015 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • New York
DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of between AQUINOX PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
AQUINOX PHARMACEUTICALS, INC. SALES AGREEMENTSales Agreement • April 1st, 2015 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • New York
Aquinox Pharmaceuticals, Inc. (the “Company”), a Delaware corporation, confirms its agreement (this “Agreement”) with Cowen and Company, LLC (“Cowen”), as follows:
AQUINOX PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF PREFERRED STOCK WARRANT AGREEMENT DATED AS OF [ ], 20Preferred Stock Warrant Agreement • December 21st, 2015 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • New York
PREFERRED STOCK WARRANT AGREEMENT (this “Agreement”), dated as of between AQUINOX PHARMACEUTICALS, INC., a Delaware corporation (the “Company”), and , a [corporation] [national banking association] organized and existing under the laws of and having a corporate trust office in , as warrant agent (the “Warrant Agent”).
LEASE AGREEMENTLease Agreement • March 12th, 2020 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations
THIS LEASE AGREEMENT (this “Lease”) is made this day of December, 2019, between ARE-EASTLAKE AVENUE NO. 3, LLC, a Delaware limited liability company (“Landlord”), and NEOLEUKIN THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
AQUINOX PHARMACEUTICALS, INC. AND , AS WARRANT AGENT FORM OF DEBT SECURITIES WARRANT AGREEMENT DATED AS OFSecurities Warrant Agreement • March 12th, 2018 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • New York
THIS DEBT SECURITIES WARRANT AGREEMENT (this “Agreement”), dated as of [•], between AQUINOX PHARMACEUTICALS, INC., a Delaware corporation (the “Company”) and [•], a [corporation] [national banking association] organized and existing under the laws of [•] and having a corporate trust office in [•], as warrant agent (the “Warrant Agent”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • December 19th, 2023 • Neurogene Inc. • Pharmaceutical preparations
This Indemnification Agreement (this “Agreement”) is entered into as of __________ by and between Neurogene Inc., a Delaware corporation (the “Company”), and __________ (the “Indemnitee”) and shall be deemed effective upon the earliest date that the Indemnitee is duly elected or appointed as a director or officer of the Company.
3,262,471 Shares of Common Stock and Pre-Funded Warrants to Purchase 1,737,529 Shares of Common Stock Neoleukin Therapeutics, Inc. UNDERWRITING AGREEMENT July 1, 2020Underwriting Agreement • July 2nd, 2020 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations • New York
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • September 20th, 2016 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • New York
This Registration Rights Agreement (this “Agreement”) is made as of September 19, 2016, by and between Aquinox Pharmaceuticals, Inc., a Delaware corporation (the “Company”), and the persons listed on the attached Schedule A who are signatories to this Agreement (collectively, the “Investors”). Unless otherwise defined herein, capitalized terms used in this Agreement have the respective meanings ascribed to them in Section 1.
Form of Executive Employment AgreementAquinox Pharmaceuticals, Inc • November 4th, 2014 • Pharmaceutical preparations • British Columbia
EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • May 8th, 2023 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations • Washington
This Executive Employment Agreement (the “Agreement”), made between Neoleukin Therapeutics, Inc., a Delaware corporation (the “Company”), and Sean Smith (the “Executive” and, collectively with the Company, the “Parties”), is entered into as of August 3, 2022 (the “Effective Date”).
LEASE AGREEMENTLease Agreement • November 13th, 2019 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations
THIS LEASE AGREEMENT (this “Lease”) is made this _____ day of September, 2019, between ARE-EASTLAKE AVENUE NO. 3, LLC, a Delaware limited liability company (“Landlord”), and NEOLEUKIN THERAPEUTICS, INC., a Delaware corporation (“Tenant”).
FORM OF CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • July 18th, 2023 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of _____, 2023, is entered into by and among Neoleukin Therapeutics, Inc., a Delaware corporation (the “Company”), [Rights Agent], as the Rights Agent, and [_________] as the Lease Representative.
5,350,000 Shares Aquinox Pharmaceuticals, Inc. COMMON STOCK, PAR VALUE $0.000001 PER SHARE UNDERWRITING AGREEMENT September 19, 2016Underwriting Agreement • September 20th, 2016 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • New York
SECURITY AGREEMENTSecurity Agreement • January 28th, 2014 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • British Columbia
AQUINOX PHARMACEUTICALS INC., a Canadian corporation incorporated under the federal laws of Canada and having its chief executive office at Suite 430, 5600 Parkwood Way, Richmond, British Columbia V6V 2M2
AMENDMENT NO. 1 TO EMPLOYMENT AGREEMENTEmployment Agreement • May 8th, 2023 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations
This Amendment No. 1 (this “Amendment”), dated as of April 3, 2023, amends that certain Employment Agreement (the “Agreement”), dated as of August 3, 2022, by and between Neoleukin Therapeutics, Inc., a Delaware corporation (the “Company”), and Sean Smith (the “Executive”). All capitalized terms not defined herein shall have the meanings assigned to them in the Agreement.
AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT for JONATHAN G. DRACHMAN, MDEmployment Agreement • April 17th, 2020 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations • Washington
This Amended and Restated Executive Employment Agreement (the “Agreement”), made between Neoleukin Therapeutics, Inc., a Delaware corporation (the “Company”), and Jonathan G. Drachman, MD (the “Executive” and, collectively with the Company, the “Parties”), is entered into as of April 15, 2020 (the “Effective Date”) and amends and restates that certain executive employment agreement entered into between the Parties as of August 5, 2019 (the “Prior Agreement”).
AMENDED AND RESTATED QUALIFICATION AND REGISTRATION RIGHTS AGREEMENTAnd Registration Rights Agreement • January 28th, 2014 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • British Columbia
WHEREAS, in connection with the execution and delivery of that certain Stock Subscription Agreement dated as of March 19, 2013 by and among the Company, the Canadian Company (as defined below) and certain of the Investors (the “Subscription Agreement”), the Company shall issue and sell shares of Series C Preferred Stock (as defined below) to certain of the Investors and the Canadian Company shall issue and sell Class C Exchangeable Shares (as defined below) to certain of the Investors;
LOAN AGREEMENTLoan Agreement • January 28th, 2014 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • British Columbia
THIS LOAN AGREEMENT (this “Agreement”) dated as of October 23, 2013 (the “Effective Date”) between SILICON VALLEY BANK, a California corporation (“Bank”), and AQUINOX PHARMACEUTICALS INC., a Canadian federal corporation (“Borrower”), provides the terms on which Bank shall lend to Borrower and Borrower shall repay Bank. The parties agree as follows:
AMENDED & RESTATED SHAREHOLDERS’ AGREEMENTShareholders’ Agreement • January 28th, 2014 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • British Columbia
FORM OF PARENT STOCKHOLDER SUPPORT AGREEMENTParent Stockholder Support Agreement • July 18th, 2023 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Support Agreement (this “Agreement”) is made and entered into as of July 17, 2023, by and among Neurogene Inc., a Delaware corporation (the “Company”), Neoleukin Therapeutics, Inc., a Delaware corporation (“Parent”), and the undersigned stockholder (the “Stockholder”) of Parent. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement.
SECURITY AGREEMENTSecurity Agreement • January 28th, 2014 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • California
This Security Agreement (this “Agreement”) is entered into as of October 23, 2013, by and between SILICON VALLEY BANK (“Bank”) and AQUINOX PHARMACEUTICALS (USA) INC., a Delaware corporation (“Pledgor”).
SCHEDULE A AQUINOX PHARMACEUTICALS INC. AQUINOX PHARMACEUTICALS (USA) INC. OPTION AGREEMENTOption Agreement • January 28th, 2014 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations
THIS AGREEMENT (the “Option Agreement”), made on the date set forth below, by and between AQUINOX PHARMACEUTICALS INC., a corporation incorporated under the federal laws of Canada (“Aquinox Canada”), AQUINOX PHARMACEUTICALS (USA) INC., a Delaware corporation (“Aquinox US”), and the Optionee named below, pursuant to the Aquinox Joint Canadian Stock Option Plan dated as of June 8, 2007, as amended from time to time (the “Plan”), a copy of which is attached hereto. Capitalized terms not otherwise defined herein have the meaning as set forth in the Plan.
AMENDMENT NO. 2 TO SHAREHOLDERS’ AGREEMENTShareholders’ Agreement • January 28th, 2014 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • British Columbia
THIS AMENDMENT NO. 2 TO SHAREHOLDERS’ AGREEMENT (this “Agreement”) is dated for reference as of November 18, 2013 among Aquinox Pharmaceuticals Inc. (the “Canadian Company”), Aquinox Pharmaceuticals (USA) Inc. (the “U.S. Company”) and certain shareholders of the Canadian Company and U.S. Company identified as such on the signature page thereto (the “Shareholders”).
AQUINOX PHARMACEUTICALS INC. Suite 430 - 5600 Parkwood Way Richmond, BC, Canada V6V 2M2 Tel Fax Web 604.629.9223 778.331.4486 www.aqxpharma.comEmployment Agreement • January 28th, 2014 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • British Columbia
This Agreement contains the terms and conditions of your employment with Aquinox Pharmaceuticals Inc. These terms of employment will commence on the Commencement Date and will continue until terminated in accordance with the provisions of this Agreement. Therefore, in consideration of your employment with the Company and the premises, the mutual covenants and agreements set forth in this Agreement and other good and valuable consideration, the receipt and sufficiency of which you hereby acknowledge, you agree as follows:
SEPARATION AGREEMENT AND RELEASESeparation Agreement and Release • December 19th, 2023 • Neurogene Inc. • Pharmaceutical preparations • Washington
This Separation Agreement and Release (this “Agreement”) is made and entered into by and between Donna Cochener (“Employee”) and Neoleukin Therapeutics, Inc. (the “Company”). The parties agree as follows:
AGREEMENT AND PLAN OF MERGER among: AQUINOX PHARMACEUTICALS, INC., a Delaware corporation; APOLLO SUB, INC., a Delaware corporation; and NEOLEUKIN THERAPEUTICS, INC., a Delaware corporation Dated as of August 5, 2019Agreement and Plan of Merger • August 6th, 2019 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • Delaware
THIS AGREEMENT AND PLAN OF MERGER (this “Agreement”) is made and entered into as of August 5, 2019, by and among AQUINOX PHARMACEUTICALS, INC., a Delaware corporation (“Parent”), APOLLO SUB, INC., a Delaware corporation and wholly owned subsidiary of Parent (“Merger Sub”), and NEOLEUKIN THERAPEUTICS, INC., a Delaware corporation (the “Company”). Certain capitalized terms used in this Agreement are defined in Exhibit A.
FORM OF COMPANY STOCKHOLDER SUPPORT AGREEMENTCompany Stockholder Support Agreement • July 18th, 2023 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations • Delaware
This Support Agreement (this “Agreement”) is made and entered into as of July 17, 2023, by and among Neurogene Inc., a Delaware corporation (the “Company”), Neoleukin Therapeutics, Inc., a Delaware corporation (“Parent”), and the undersigned stockholder (the “Stockholder”) of the Company. Capitalized terms used herein but not otherwise defined shall have the respective meanings ascribed to such terms in the Merger Agreement.
ContractAsset Purchase Agreement • February 28th, 2014 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • British Columbia
[*] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS FILED WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 UNDER THE SECURITIES ACT OF 1933, AS AMENDED.
CONTINGENT VALUE RIGHTS AGREEMENTContingent Value Rights Agreement • December 19th, 2023 • Neurogene Inc. • Pharmaceutical preparations • Delaware
THIS CONTINGENT VALUE RIGHTS AGREEMENT (this “Agreement”), dated as of December 18, 2023, is entered into by and among Neoleukin Therapeutics, Inc., a Delaware corporation (the “Company”), Equiniti Trust Company, LLC, a New York limited liability trust company, as the Rights Agent, and Donna Cochener as the Lease Representative.
= CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. LICENCE AGREEMENT between THE UNIVERSITY...Licence Agreement • November 8th, 2023 • Neoleukin Therapeutics, Inc. • Pharmaceutical preparations
THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH, a charitable body registered in Scotland under registration number SC005336, incorporated under the Universities (Scotland) Acts and having its main administrative offices at Old College, South Bridge Edinburgh, EH8 9YL (the “University”);
ContractAssignment Agreement • January 28th, 2014 • Aquinox Pharmaceuticals, Inc • Pharmaceutical preparations • California
THIS WARRANT AND THE SHARES ISSUABLE HEREUNDER HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “ACT”), OR THE SECURITIES LAWS OF ANY STATE AND, EXCEPT AS SET FORTH IN SECTIONS 5.3 AND 5.4 BELOW, MAY NOT BE OFFERED, SOLD, PLEDGED OR OTHERWISE TRANSFERRED UNLESS AND UNTIL REGISTERED UNDER SAID ACT AND LAWS OR IN FORM AND SUBSTANCE SATISFACTORY TO THE COMPANY, SUCH OFFER, SALE, PLEDGE OR OTHER TRANSFER IS EXEMPT FROM SUCH REGISTRATION.
